Clinical value of ambulatory blood pressure: Is it time to recommend for all patients with hypertension?

Clinical and Experimental Nephrology

Volumn 20, Issue 1, 2016, Pages 14-22

  Solak, Yalcin ^a   Kario, Kazuomi ^b   Covic, Adrian ^c   Bertelsen, Nathan ^d   Afsar, Baris ^e   Ozkok, Abdullah ^f   Wiecek, Andrzej ^g   Kanbay, Mehmet ^d  

^a SAKARYA UNIVERSITY   (Turkey)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^d KOÇ UNIVERSITY   (Turkey)

^e Konya Numune State Hospital   (Turkey)

^f ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Ambulatory blood pressure monitoring; Cardiovascular disease; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CHRONOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MASKED HYPERTENSION; WHITE COAT HYPERTENSION; BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECTS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DISEASE PROGRESSION; HUMANS; HYPERTENSION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84958675065     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-015-1184-1     Document Type: Article

References (61)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399–410.
2. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52(5):818–27.
3. Turner JR, Viera AJ, Shimbo D. Ambulatory blood pressure monitoring in clinical practice: a review. Am J Med. 2015;128(1):14–20.
4. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens. 2012;30(7):1289–99.
5. Head GA. Ambulatory blood pressure monitoring is ready to replace clinic blood pressure in the diagnosis of hypertension: pro side of the argument. Hypertension. 2014;64(6):1175–81 discussion 81.
6. Redon J, Lurbe E. Ambulatory blood pressure monitoring is ready to replace clinic blood pressure in the diagnosis of hypertension: con side of the argument. Hypertension. 2014;64(6):1169–74 discussion 74.
7. Franklin SS, Thijs L, Hansen TW, O’Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. Hypertension. 2013;62(6):982–7.
8. Ogedegbe G. Labeling and hypertension: it is time to intervene on its negative consequences. Hypertension. 2010;56(3):344–5.
9. National Institute for Health and Care Excellence. Clinical guideline 127. Hypertension: clinical management of primary hypertension in adults. 2011 [09/05/2015]. http://guidance.nice.org.uk/CG127/Guidance
10. Hermida RC, Smolensky MH, Ayala DE, Portaluppi F. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013;30(3):355–410.
11. Terawaki H, Metoki H, Nakayama M, Ohkubo T, Kikuya M, Asayama K, et al. Masked hypertension determined by self-measured blood pressure at home and chronic kidney disease in the Japanese general population: the Ohasama study. Hypertens Res. 2008;31(12):2129–35.
12. Hermida RC, Ayala DE, Smolensky MH, Fernandez JR, Mojon A, Crespo JJ, et al. Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders. Curr Hypertens Rep. 2014;16(2):412.
13. Kanbay M, Turkmen K, Ecder T, Covic A. Ambulatory blood pressure monitoring: from old concepts to novel insights. Int Urol Nephrol. 2012;44(1):173–82.
14. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.
15. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. 2011;342:d3621.
16. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA. 1988;259(2):225–8.
17. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731–68.
18. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25(11):2193–8.
19. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54(2):226–32.
20. Ugajin T, Hozawa A, Ohkubo T, Asayama K, Kikuya M, Obara T, et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med. 2005;165(13):1541–6.
21. Stergiou GS, Salgami EV, Tzamouranis DG, Roussias LG. Masked hypertension assessed by ambulatory blood pressure versus home blood pressure monitoring: is it the same phenomenon? Am J Hypertens. 2005;18(6):772–8.
22. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 2002;40(6):795–6.
23. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens. 2011;24(1):52–8.
24. Franklin SS, O’Brien E, Thijs L, Asayama K, Staessen JA. Masked hypertension: a phenomenon of measurement. Hypertension. 2015;65(1):16–20.
25. Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28(10):2036–45.
26. Hansen TW, Kikuya M, Thijs L, Bjorklund-Bodegard K, Kuznetsova T, Ohkubo T, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals. J Hypertens. 2007;25(8):1554–64.
27. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111(14):1777–83.
28. Niiranen TJ, Maki J, Puukka P, Karanko H, Jula AM. Office, home, and ambulatory blood pressures as predictors of cardiovascular risk. Hypertension. 2014;64(2):281–6.
29. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):2407–15.
30. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklund-Bodegard K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219–29.
31. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension. 2007;49(6):1235–41.
32. Kanbay M, Turgut F, Uyar ME, Akcay A, Covic A. Causes and mechanisms of nondipping hypertension. Clin Exp Hypertens. 2008;30(7):585–97.
33. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension. 2006;47(2):149–54.
34. Ingelsson E, Bjorklund-Bodegard K, Lind L, Arnlov J, Sundstrom J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA. 2006;295(24):2859–66.
35. Kario K. Prognosis in relation to blood pressure variability: pro side of the argument. Hypertension. 2015;65(6):1163–9.
36. Tai C, Sun Y, Dai N, Xu D, Chen W, Wang J, et al. Prognostic significance of visit-to-visit systolic blood pressure variability: a meta-analysis of 77,299 patients. J Clin Hypertens (Greenwich). 2015;17(2):107–15.
37. Hoshide S, Kario K, Hoshide Y, Umeda Y, Hashimoto T, Kunii O, et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens. 2003;16(6):434–8.
38. Conway KS, Forbang N, Beben T, Criqui MH, Ix JH, Rifkin DE. Relationship between 24-hour ambulatory blood pressure and cognitive function in community-living older adults: The UCSD Ambulatory Blood Pressure Study. Am J Hypertens. 2015.
39. Takeda N, Maemura K. Circadian clock and cardiovascular disease. J Cardiol. 2011;57(3):249–56.
40. Takeda N, Maemura K. Cardiovascular disease, chronopharmacotherapy, and the molecular clock. Adv Drug Deliv Rev. 2010;62(9–10):956–66.
41. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27(8):1629–51.
42. Liu X, Huang W, Leo S, Li Y, Liu M, Yuan H. Evening -versus morning- dosing drug therapy for chronic kidney disease patients with hypertension: a systematic review. Kidney Blood Press Res. 2014;39(5):427–40.
43. Kasiakogias A, Tsioufis C, Thomopoulos C, Andrikou I, Aragiannis D, Dimitriadis K, et al. Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study. J Hypertens. 2015;33(2):393–400.
44. Minutolo R, Borrelli S, Scigliano R, Bellizzi V, Chiodini P, Cianciaruso B, et al. Prevalence and clinical correlates of white coat hypertension in chronic kidney disease. Nephrol Dial Transplant. 2007;22(8):2217–23.
45. Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V, Nappi F, et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med. 2011;171(12):1090–8.
46. Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension. 2010;55(3):762–8.
47. Roberts MA, Pilmore HL, Tonkin AM, Garg AX, Pascoe EM, Badve SV, et al. Challenges in blood pressure measurement in patients treated with maintenance hemodialysis. Am J Kidney Dis. 2012;60(3):463–72.
48. Yarows SA, Khoury S, Sowers JR. Cost effectiveness of 24-hour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension. Am J Hypertens. 1994;7(5):464–8.
49. Pessanha P, Viana M, Ferreira P, Bertoquini S, Polonia J. Diagnostic value and cost-benefit analysis of 24 hours ambulatory blood pressure monitoring in primary care in Portugal. BMC Cardiovasc Disord. 2013;13:57.
50. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378(9798):1219–30.
51. Bloomfield GL, Blocher CR, Fakhry IF, Sica DA, Sugerman HJ. Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels. J Trauma. 1997;42(6):997–1004 discussion -5.
52. Ambulatory blood pressure monitoring. Aust Fam Physician. 2011;40(11):877–80.
53. Campbell NR, Hemmelgarn BR. New recommendations for the use of ambulatory blood pressure monitoring in the diagnosis of hypertension. CMAJ. 2012;184(6):633–4.
54. Japanese Circulation Society Joint Working Group. Guidelines for the clinical use of 24 hour ambulatory blood pressure monitoring (ABPM) (JCS 2010): digest version. Circ J. 2012;76:508–19.
55. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291–7.
56. Kaplan NM. Resistant hypertension. J Hypertens. 2005;23(8):1441–4.
57. Portaluppi F, Montanari L, Massari M, Di Chiara V, Capanna M. Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure. Am J Hypertens. 1991;4(1 Pt 1):20–6.
58. Mizuno M, Fukuda M, Miura T, Wakamatsu T, Naito T, Sato R, et al. Morning hypertension in chronic kidney disease is sustained type, but not surge type. Blood Press Monit. 2012;17(1):20–3.
59. Cohen DL, Huan Y, Townsend RR. Ambulatory blood pressure in chronic kidney disease. Curr Hypertens Rep. 2013;15(3):160–6.
60. Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol: CJASN. 2009;4(4):830–7.
61. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015.